TITLE:
Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease

CONDITION:
Graft Vs Host Disease

INTERVENTION:
ABX-CBL

SUMMARY:

      Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus
      ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does
      not respond to steroid therapy.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 1 Year to N/A
Criteria:

        Inclusion Criteria:

          -  Recipient of single allogeneic stem cell transplant from any donor type

          -  Time post transplant less than 100 days

          -  Received no treatment for GVHD other than steroids

        Exclusion Criteria:

          -  Recipient of second allogeneic stem cell transplant or subsequent lymphocyte product
             from the donor post transplant

          -  IBMTR index less than A

          -  Received any murine product in the past

          -  Diagnosed with chronic GVHD

          -  Received Atgam later than day 10 post transplant

          -  Change to prophylactic regimen for acute GVHD within 72 hours of randomization
      
